About 6% of Americans with obesity and without diabetes have had surgery or taken GLP-1 agonists, the research team estimates ...

Rapid weight loss can cause a greater loss of muscle mass than losing weight slowly. The popularity of newer weight-loss ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

“When we compare bariatric surgery to bariatric endoscopy ... and to discover differences between comparing the two ...

In animal models, GLP-1 agonists have been shown to reduce neuroinflammation ... After propensity-score matching, comparison groups were balanced. Mean baseline age was 58, and about 40% were ...

Use of sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs to treat type 2 diabetes may also help to lower the risk of ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Evoke Pharma reports positive results for a study on GIMOTI. Evoke Pharma stock has now tripled since early September.